Novasenta will use a machine learning-enabled platform developed by University of Pittsburgh scientists to investigate immunotherapies that target the tumor microenvironment. Novasenta hopes to launch its first clinical trial by the end of 2023.

The company's proprietary discovery platform applies single-cell transcriptomics analysis, unique immune cell assays, animal models, and machine learning-enabled data interrogation and management, with the goal of discovering novel, druggable targets and developing the next generation of safe and effective therapeutics.

The company was founded by three UPMC and University of Pittsburgh scientists. UPMC invested in Novasenta through the health system's innovation and capital arm, UPMC Enterprises.